The US Food and Drug Administration (FDA) has approved Boston Scientific’s Agent Drug-Coated Balloon (DCB), the first coronary DCB for the treatment of coronary in-stent restenosis in patients with coronary artery disease, the company has announced in a news release. In-stent restenosis makes up an estimated 10% of percutaneous coronary interventions in the United States. …
Read More
